Preparing for the long-haul: Autonomic complications of COVID-19.
Nicholas W Larsen, Lauren E Stiles, Mitchell G Miglis
https://pubmed.ncbi.nlm.nih.gov/34265539/Actively Recruiting
Led by Stanford University · Updated on 2026-10-28
20
Participants Needed
2
Research Sites
N/A
Total Duration
Postural Tachycardia Syndrome POTS is a condition affecting mainly young women and causes symptoms such as lightheadedness, cognitive problems, blurred vision, irritability, palpitations, and chest discomfort when standing. These symptoms improve when lying down but many patients remain significantly disabled despite current treatments. This research aims to evaluate the effects of stellate ganglion block SGB as a potential non-drug treatment for symptom control in POTS through a randomized controlled trial. In this study, 20 patients with POTS will be randomly assigned to one of two groups one will receive an ultrasound-guided stellate ganglion block with 10 ml of 0.5% ropivacaine, while the other will receive a sham saline injection under ultrasound guidance to simulate the procedure. The trial aims to compare heart rate, markers of sympathetic activity, and POTS symptoms between the groups to assess the interventions impact. Participants will be evaluated before the intervention and followed up at two time points shortly after the procedure days 1 to 21 and later days 74 to 94. During these visits, researchers will measure symptoms using the COMPASS 31 score and other tests including heart rate variability, plasma catecholamine levels, and various symptom surveys. Safety and tolerability will also be monitored immediately after the procedure. The study is conducted over several months with three follow-up visits to assess both immediate and long-term outcomes.
CONDITIONS
Ultrasound Guided Stellate Ganglion Block in Postural Tachycardia Syndrome
A
Anna Maria Bombardieri, MD, PhD
K
Ksenia Kasimova, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Stanford University
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | SGB with Ropivacaine | Sham Injection | Current Standard Therapy |
|---|---|---|---|
| What is it? | A nerve block procedure targeting the stellate ganglion, performed under ultrasound guidance, using the anesthetic ropivacaine. | A sham (placebo) procedure where participants receive a subcutaneous injection of normal saline without targeting the actual stellate ganglion. | A combination of non-invasive strategies including education, increasing fluid and salt intake, physical counter-maneuvers, exercise, and individualized use of medications if appropriate. |
| Role in the study | Investigational procedure tested to see if it reduces symptoms of POTS. | Used as a placebo comparator so effects of SGB can be evaluated. | Not randomized in this trial; represents how POTS is typically managed outside research settings. |
| Main purpose or goal | To evaluate if blocking sympathetic nerve traffic with SGB relieves the symptoms and autonomic dysfunction in POTS. | To serve as a placebo, allowing comparison with the true nerve block procedure. | Aims to improve daily symptoms and function in people with POTS using stepwise, evidence-informed approaches. |
| How is it performed? | A local anesthetic (ropivacaine) is injected around the stellate ganglion in the neck under ultrasound guidance. | A small amount of saline is injected under the skin near the same area, but does not block the nerve. | Includes education, advice on fluid and salt intake, exercise guidance, use of support garments, physical counter-maneuvers, and tailored medications if non-drug therapies are insufficient. |
| Published evidence status | Efficacy for treating POTS is under clinical investigation; results not yet established in this patient population. | Placebo used to compare against real SGB; does not have therapeutic effect for POTS. | Non-drug and drug treatments are recommended based on evidence from clinical studies and expert consensus. SGB is not part of guideline-based therapy. |
| Important limitations | Not yet established as safe or effective for POTS; limited published evidence in this population. | No expected benefit; used for research comparison only. | Current treatments often improve symptoms but many patients continue to experience persistent symptoms or incomplete relief. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 day
Participants receive either an ultrasound-guided stellate ganglion block with ropivacaine or a sham saline injection under ultrasound guidance.
1 treatment visit
Duration - Up to 94 days
Participants return for two follow-up visits to assess symptoms and measures using questionnaires, heart rate tests, and blood samples.
2 follow-up visits
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Nicholas W Larsen, Lauren E Stiles, Mitchell G Miglis
https://pubmed.ncbi.nlm.nih.gov/34265539/Lisa Pearson, Alfred Maina, Taylor Compratt...
https://pubmed.ncbi.nlm.nih.gov/37711269/Taylor A Doherty, Andrew A White
https://pubmed.ncbi.nlm.nih.gov/30033040/Deborah Duricka, Luke Liu
https://pubmed.ncbi.nlm.nih.gov/38901177/Yong-Mei Cha, Xuping Li, Mei Yang...
https://pubmed.ncbi.nlm.nih.gov/31625219/Steven Vernino, Kate M Bourne, Lauren E Stiles...
https://pubmed.ncbi.nlm.nih.gov/34144933/Stanford University
Lead Sponsor